Siakallis George, Spandidos Demetrios A, Sourvinos George
Department of Virology, Faculty of Medicine, University of Crete, Crete, Greece.
Antivir Ther. 2009;14(8):1051-64. doi: 10.3851/IMP1467.
Herpesviridae comprises a large family of double-stranded DNA viruses that infect both animals and humans. Eight herpesviruses are known to infect humans: herpes simplex virus type-1 and -2, varicella zoster virus, human cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 type-A and -B, human herpesvirus type-7 and -8 or Kaposi's sarcoma virus. Despite the fact that the past two decades have been evolutionary in the development of antiviral agents, therapeutic choices are restricted by limited efficacy and toxicity. Viral infections remain the cause of significant mortality worldwide, thus indicating the high medical need for the introduction of novel promising compounds in the antiviral chemotherapy era. This review focuses on recent data regarding several novel groups of agents that have proved to be effective as antiherpetic drugs. The agents mentioned are those considered to be the most likely candidates for entering clinical trials and those in the process of being granted approval by the US Food and Drug Administration. The diversity in their molecular mechanism of action highlights the different perspectives currently encountered in the era of antiviral therapy.
疱疹病毒科是一个庞大的双链DNA病毒家族，可感染动物和人类。已知有八种疱疹病毒可感染人类：1型和2型单纯疱疹病毒、水痘带状疱疹病毒、人巨细胞病毒、爱泼斯坦-巴尔病毒、A型和B型人疱疹病毒6型、人疱疹病毒7型和8型或卡波西肉瘤病毒。尽管在过去二十年中抗病毒药物的研发取得了进展，但治疗选择仍受到疗效有限和毒性的限制。病毒感染仍然是全球重大死亡的原因，这表明在抗病毒化疗时代，迫切需要引入有前景的新型化合物。本综述重点关注了几类新型药物的最新数据，这些药物已被证明是有效的抗疱疹药物。所提及的药物是那些被认为最有可能进入临床试验的药物，以及正在获得美国食品药品监督管理局批准的药物。它们作用的分子机制的多样性凸显了抗病毒治疗时代目前所面临的不同观点。
